Mark Underwood

4.9k total citations · 1 hit paper
55 papers, 2.8k citations indexed

About

Mark Underwood is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Mark Underwood has authored 55 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Infectious Diseases, 36 papers in Virology and 17 papers in Molecular Biology. Recurrent topics in Mark Underwood's work include HIV/AIDS drug development and treatment (38 papers), HIV Research and Treatment (36 papers) and Biochemical and Molecular Research (13 papers). Mark Underwood is often cited by papers focused on HIV/AIDS drug development and treatment (38 papers), HIV Research and Treatment (36 papers) and Biochemical and Molecular Research (13 papers). Mark Underwood collaborates with scholars based in United States, United Kingdom and Japan. Mark Underwood's co-authors include Tamio Fujiwara, Karen K. Biron, Leroy B. Townsend, John C. Drach, Brian A. Johns, Takahiro Seki, Akihiko Sato, Howard M. Fried, Tomokazu Yoshinaga and Clifford I. Voss and has published in prestigious journals such as The Lancet, The EMBO Journal and PLoS ONE.

In The Last Decade

Mark Underwood

52 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

2018 243 citations Josep M. Llibre, Chien‐Ching Hung et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Underwood United States	25	1.9k	1.7k	871	642	239	55	2.8k
Marty St. Clair United States	27	1.9k 1.0×	1.9k 1.1×	609 0.7×	277 0.4×	354 1.5×	66	2.9k
David Marchant Canada	24	549 0.3×	152 0.1×	1.1k 1.3×	642 1.0×	17 0.1×	61	2.5k
Margaret Keller United States	22	321 0.2×	109 0.1×	238 0.3×	271 0.4×	55 0.2×	75	1.8k
Jurgen Vercauteren Belgium	15	504 0.3×	273 0.2×	169 0.2×	57 0.1×	47 0.2×	36	942
Carlo Torti Italy	20	1.1k 0.6×	906 0.5×	279 0.3×	140 0.2×	314 1.3×	65	1.4k
Andrea Costantini Italy	15	256 0.1×	280 0.2×	213 0.2×	147 0.2×	137 0.6×	59	832
Sophie Limou France	20	213 0.1×	162 0.1×	144 0.2×	257 0.4×	114 0.5×	54	1.5k
Manabu Aoki Japan	23	700 0.4×	583 0.3×	279 0.3×	227 0.4×	47 0.2×	105	1.5k
Ryuji Kawaguchi Japan	27	257 0.1×	35 0.0×	626 0.7×	709 1.1×	13 0.1×	115	2.6k
Daniel S Berger United States	10	879 0.5×	767 0.5×	116 0.1×	157 0.2×	189 0.8×	21	1.3k

Countries citing papers authored by Mark Underwood

Since Specialization

Citations

This map shows the geographic impact of Mark Underwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Underwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Underwood more than expected).

Fields of papers citing papers by Mark Underwood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Underwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Underwood. The network helps show where Mark Underwood may publish in the future.

Co-authorship network of co-authors of Mark Underwood

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Underwood. A scholar is included among the top collaborators of Mark Underwood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Underwood. Mark Underwood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Underwood, Mark, José Castillo‐Mancilla, Lesley Kahl, et al.. (2025). Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clinical Infectious Diseases. 81(3). 510–520.

Rolle, Charlotte-Paige, José Ramón Arribas, Roberto Ortiz, et al.. (2025). Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials. Open Forum Infectious Diseases. 12(3). ofaf135–ofaf135.

Underwood, Mark, Ruolan Wang, J Oyee, et al.. (2024). Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies. Viruses. 16(3). 405–405. 2 indexed citations

Mehta, Rashmi, Konstantinos Angelis, Lesley Kahl, et al.. (2023). Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies. British Journal of Clinical Pharmacology. 89(7). 2190–2200. 2 indexed citations

Rolle, Charlotte-Paige, Mezgebe Berhe, Tulika Singh, et al.. (2023). Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks. Open Forum Infectious Diseases. 10(3). ofad101–ofad101. 11 indexed citations

Wang, Ruolan, Jonathan Wright, Mounir Ait‐Khaled, et al.. (2023). Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144. Viruses. 15(6). 1350–1350. 1 indexed citations

Rolle, Charlotte-Paige, Mezgebe Berhe, Tulika Singh, et al.. (2021). 75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study. Open Forum Infectious Diseases. 8(Supplement_1). S49–S49. 1 indexed citations

Aboud, Michael, Chloe Orkin, Daniel Podzamczer, et al.. (2019). Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. The Lancet HIV. 6(9). e576–e587. 77 indexed citations

Aboud, Michael, Richard Kaplan, Johannes Lombaard, et al.. (2019). Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. The Lancet Infectious Diseases. 19(3). 253–264. 104 indexed citations

10.

Demarest, James F., Mark Underwood, Marty St. Clair, et al.. (2018). Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance. AIDS Research and Human Retroviruses. 34(4). 343–346. 16 indexed citations

11.

Llibre, Josep M., Chien‐Ching Hung, Cynthia Brinson, et al.. (2018). Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. The Lancet. 391(10123). 839–849. 243 indexed citations breakdown →

12.

Canducci, Filippo, Elisa Rita Ceresola, Diego Saita, et al.. (2013). In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. Journal of Antimicrobial Chemotherapy. 68(11). 2525–2532. 24 indexed citations

13.

Deanda, Felix, Kendra E. Hightower, Robert T. Nolte, et al.. (2013). Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics. PLoS ONE. 8(10). e77448–e77448. 44 indexed citations

14.

Min, Sherene, Louis Sloan, Edwin DeJesus, et al.. (2011). Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 25(14). 1737–1745. 171 indexed citations

15.

Hightower, Kendra E., Ruolan Wang, Felix Deanda, et al.. (2011). Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes. Antimicrobial Agents and Chemotherapy. 55(10). 4552–4559. 182 indexed citations

16.

Nakahara, Koichiro, Chiaki Wakasa-Morimoto, Masanori Kobayashi, et al.. (2008). Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Research. 81(2). 141–146. 46 indexed citations

17.

Underwood, Mark, Lisa Ross, David M. Irlbeck, et al.. (2008). Sensitivity of Phenotypic Susceptibility Analyses for Nonthymidine Nucleoside Analogues Conferred by K65R or M184V in Mixtures with Wild-Type HIV-1. The Journal of Infectious Diseases. 199(1). 84–88. 9 indexed citations

18.

Ross, Lisa, Neil Parkin, Peter Gerondelis, et al.. (2006). Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine Susceptibility. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(5). 567–570. 7 indexed citations

19.

Givens, Naomi, Christopher Stone, Philip Griffin, et al.. (2004). Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens. HIV Medicine. 5(6). 394–399. 30 indexed citations

20.

Chulay, Jeffrey D., Karen K. Biron, Mark Underwood, et al.. (1999). Development of Novel Benzimidazole Riboside Compounds for Treatment of Cytomegalovirus Disease. Advances in experimental medicine and biology. 458. 129–134. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact